Moreover, the GPR40 agonists could reduce inflammatory signaling, such as NF-κB, IL-1β, TNF-α, and NOS2α, in the mouse NIT1 insulinoma cells and rat islets that are under chronic inflammatory conditions [70] and LPS-induced activation of IKK in BV2 cells [71]. Here, NIT1 is linked to pancreatic insulinoma.